Spyre Therapeutics has appointed Kate Tansey Chevlen as Chief Commercial Officer.
Tansey Chevlen most recently held the role of Vice President, Global Marketing Head for Immunology and Inflammation at Amgen. She served at Amgen for over 17 years, with other roles including Vice President Patient Access and Reimbursement and Executive Director Respiratory Marketing and Sales. During this time, she assisted with various successful product launches and helped lead sales and marketing initiatives.
Tansey Chevlen brings extensive expertise in both market and patient access strategy to her new role, having worked closely alongside multiple cross-functional teams during her time at Amgen.
The appointment of Tansey Chevlen will help to drive Spyre’s future growth. The company recently announced expected readouts from multiple clinical trials across 2026, including for moderate to severe ulcerative colitis, moderate to severe rheumatoid arthritis and psoriatic arthritis.
Cameron Turtle, CEO of Spyre, said: “As we plan to initiate late-stage development in 2027, we are excited to welcome Kate as our new CCO. Kate’s experience securing access and driving product uptake will be invaluable as we shape our phase 3 strategy.”
Tansey Chevlen added: “I am thrilled to join Spyre at this critical juncture as we deliver proof-of-concept data and prepare to execute pivotal trials and commercialise highly differentiated products.”